Concepts (64)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Virtual Reality | 1 | 2020 | 37 | 0.600 |
Why?
|
| Alagille Syndrome | 1 | 2008 | 5 | 0.290 |
Why?
|
| Moyamoya Disease | 1 | 2008 | 21 | 0.280 |
Why?
|
| Aneurysm, Ruptured | 1 | 2008 | 61 | 0.280 |
Why?
|
| Cerebral Ventricles | 1 | 2024 | 66 | 0.210 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2024 | 153 | 0.190 |
Why?
|
| Brain Neoplasms | 3 | 2013 | 813 | 0.180 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2024 | 461 | 0.170 |
Why?
|
| Histiocytic Sarcoma | 1 | 2016 | 7 | 0.130 |
Why?
|
| Orbital Neoplasms | 1 | 2016 | 16 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2585 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2715 | 0.100 |
Why?
|
| Electric Stimulation Therapy | 1 | 2013 | 53 | 0.090 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2012 | 14 | 0.090 |
Why?
|
| Cerebral Angiography | 2 | 2008 | 211 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2013 | 281 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 398 | 0.080 |
Why?
|
| Orbital Cellulitis | 1 | 2009 | 4 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 291 | 0.080 |
Why?
|
| Abscess | 1 | 2009 | 94 | 0.070 |
Why?
|
| X-Ray Microtomography | 1 | 2008 | 101 | 0.070 |
Why?
|
| Thyroid Neoplasms | 1 | 2012 | 442 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2009 | 297 | 0.060 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2006 | 4 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 2544 | 0.060 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2006 | 40 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1448 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 1001 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 157 | 0.060 |
Why?
|
| Humans | 9 | 2024 | 93515 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 1173 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2006 | 367 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 1133 | 0.050 |
Why?
|
| Female | 6 | 2024 | 48702 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2024 | 1922 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 2365 | 0.040 |
Why?
|
| Middle Aged | 5 | 2024 | 27573 | 0.040 |
Why?
|
| Algorithms | 1 | 2024 | 1953 | 0.030 |
Why?
|
| Aged | 3 | 2024 | 20434 | 0.030 |
Why?
|
| Adult | 3 | 2009 | 27918 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 165 | 0.020 |
Why?
|
| Thyrotoxicosis | 1 | 2012 | 18 | 0.020 |
Why?
|
| Male | 4 | 2024 | 44557 | 0.020 |
Why?
|
| Thyroglobulin | 1 | 2012 | 59 | 0.020 |
Why?
|
| Mitosis | 1 | 2012 | 150 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 295 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2012 | 173 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 3476 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 256 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3829 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2009 | 233 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2012 | 317 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1723 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 1799 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1234 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 626 | 0.010 |
Why?
|
| Contrast Media | 1 | 2009 | 988 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2012 | 1691 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 9099 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1546 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 2017 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 7061 | 0.010 |
Why?
|
| Child | 1 | 2009 | 7355 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 10164 | 0.010 |
Why?
|